Are Prescribing Doctors Sensitive to the Price That Their Patients Have to Pay in the Spanish National Health System?

Overview

Journal BMC Health Serv Res

Publisher Biomed Central

Specialty Health Services

Date 2011 Dec 14

PMID 22151628

Citations 3

Authors

Beatriz Gonzalez Lopez-Valcarcel

Julian Librero

Gabriel Sanfelix-Gimeno

Salvador Peiro

Affiliations

Soon will be listed here.

Abstract

Background: This study aims to design an empirical test on the sensitivity of the prescribing doctors to the price afforded for the patient, and to apply it to the population data of primary care dispensations for cardiovascular disease and mental illness in the Spanish National Health System (NHS). Implications for drug policies are discussed.

Methods: We used population data of 17 therapeutic groups of cardiovascular and mental illness drugs aggregated by health areas to obtain 1424 observations ((8 cardiovascular groups * 70 areas) + (9 psychotropics groups * 96 areas)). All drugs are free for pensioners. For non-pensioner patients 10 of the 17 therapeutic groups have a reduced copayment (RC) status of only 10% of the price with a ceiling of €2.64 per pack, while the remaining 7 groups have a full copayment (FC) rate of 40%. Differences in the average price among dispensations for pensioners and non-pensioners were modelled with multilevel regression models to test the following hypothesis: 1) in FC drugs there is a significant positive difference between the average prices of drugs prescribed to pensioners and non-pensioners; 2) in RC drugs there is no significant price differential between pensioner and non-pensioner patients; 3) the price differential of FC drugs prescribed to pensioners and non-pensioners is greater the higher the price of the drugs.

Results: The average monthly price of dispensations to pensioners and non-pensioners does not differ for RC drugs, but for FC drugs pensioners get more expensive dispensations than non-pensioners (estimated difference of €9.74 by DDD and month). There is a positive and significant effect of the drug price on the differential price between pensioners and non-pensioners. For FC drugs, each additional euro of the drug price increases the differential by nearly half a euro (0.492). We did not find any significant differences in the intensity of the price effect among FC therapeutic groups.

Conclusions: Doctors working in the Spanish NHS seem to be sensitive to the price that can be afforded by patients when they fill in prescriptions, although alternative hypothesis could also explain the results found.

Citing Articles

Which factor reduces pharmaceutical expenditure, number of entrants or price variance? Updated generic drug markets in South Korea.

Son K Health Econ Rev. 2024; 14(1):64.

PMID: 39141190 PMC: 11323484. DOI: 10.1186/s13561-024-00545-z.

A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region.

Garcia-Sempere A, Bejarano-Quisoboni D, Librero J, Rodriguez-Bernal C, Peiro S, Sanfelix-Gimeno G Front Pharmacol. 2017; 8:576.

PMID: 28883793 PMC: 5573806. DOI: 10.3389/fphar.2017.00576.

The effects of introducing an electronic prescription system with no copayments.

Eriksen I, Melberg H Health Econ Rev. 2015; 5(1):56.

PMID: 26174807 PMC: 4502047. DOI: 10.1186/s13561-015-0056-4.

References

Kasje W, Timmer J, Boendermaker P, Haaijer-Ruskamp F . Dutch GPs' perceptions: the influence of out-of-pocket costs on prescribing. Soc Sci Med. 2002; 55(9):1571-8. DOI: 10.1016/s0277-9536(01)00291-x. View

Shrank W, Joseph G, Choudhry N, Young H, Ettner S, Glassman P . Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most?. Am J Manag Care. 2006; 12(9):545-51. View

Puig-Junoy J . [The financing and price regulation of drugs in the Spanish National Health System: changes and continuity]. Gac Sanit. 2007; 21(1):1-4. DOI: 10.1016/s0213-9111(07)71961-1. View

Sanfelix-Gimeno G, Peiro S, Librero J, Ausejo-Segura M, Suarez-Aleman C, Molina-Lopez T . [Population analysis by area of health of changes in consumption, price and expenditure of cardiovascular drugs in eight autonomous communities, Spain, 2005]. Rev Esp Salud Publica. 2010; 84(4):389-407. View

. Better pharmaceutical price comparison studies are needed for meaningful evaluation of price-control policies. Value Health. 2008; 11(1):129-30. DOI: 10.1111/j.1524-4733.2007.00300.x. View

Martin-Moreno J, Alonso P, Claveria A, Gorgojo L, Peiro S . Spain: a decentralised health system in constant flux. BMJ. 2009; 338:b1170. DOI: 10.1136/bmj.b1170. View

Pham H, Alexander G, OMalley A . Physician consideration of patients' out-of-pocket costs in making common clinical decisions. Arch Intern Med. 2007; 167(7):663-8. DOI: 10.1001/archinte.167.7.663. View

Khan S, Sylvester R, Scott D, Pitts B . Physicians' opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern states. J Manag Care Pharm. 2008; 14(8):780-9. PMC: 10437318. DOI: 10.18553/jmcp.2008.14.8.780. View

Iizuka T . Experts' agency problems: evidence from the prescription drug market in Japan. Rand J Econ. 2008; 38(3):844-62. DOI: 10.1111/j.0741-6261.2007.00115.x. View

10.

Reichert S, Simon T, Halm E . Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med. 2000; 160(18):2799-803. DOI: 10.1001/archinte.160.18.2799. View

11.

Shrank W, Asch S, Joseph G, Young H, Ettner S, Kholodenko Y . Physicians' perceived knowledge of and responsibility for managing patients' out-of-pocket costs for prescription drugs. Ann Pharmacother. 2006; 40(9):1534-40. DOI: 10.1345/aph.1H158. View

12.

Alexander G, Casalino L, Meltzer D . Physician strategies to reduce patients' out-of-pocket prescription costs. Arch Intern Med. 2005; 165(6):633-6. DOI: 10.1001/archinte.165.6.633. View

13.

Beran M, Laouri M, Suttorp M, Brook R . Medication costs: the role physicians play with their senior patients. J Am Geriatr Soc. 2007; 55(1):102-7. DOI: 10.1111/j.1532-5415.2006.01011.x. View

14.

Alastrue Loscos J, Meneu de Guillerna R, Peiro Moreno S . [Analysis of opinions, attitudes and knowledge of physicians of health centers of Valencia concerning efficacy and efficiency of drug prescriptions]. Aten Primaria. 1998; 21(3):165-71. View

15.

Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman A, Sturm H . Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008; (1):CD007017. DOI: 10.1002/14651858.CD007017. View

16.

Lundin D . Moral hazard in physician prescription behavior. J Health Econ. 2001; 19(5):639-62. DOI: 10.1016/s0167-6296(00)00033-3. View

17.

Gleason P, Starner C, Gunderson B, Schafer J, Sarran H . Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009; 15(8):648-58. PMC: 10441203. DOI: 10.18553/jmcp.2009.15.8.648. View

18.

Allan G, Lexchin J, Wiebe N . Physician awareness of drug cost: a systematic review. PLoS Med. 2007; 4(9):e283. PMC: 1989748. DOI: 10.1371/journal.pmed.0040283. View

19.

Alexander G, Casalino L, Meltzer D . Patient-physician communication about out-of-pocket costs. JAMA. 2003; 290(7):953-8. DOI: 10.1001/jama.290.7.953. View